Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Latanoprost · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Participants will receive up to 3 multiple ascending dose levels with the starting dose of 0.1% RO5093151 (topical ocular instillation) and sequentially 0.5% and 1% RO5093151 doses or placebo (3:1, active:placebo) twice a day (BID) on Day 1 and once a day (QD) for 6 days. |
| Part B | EXPERIMENTAL | Participants will receive highest feasible dose (HFD) or maximum tolerated dose (MTD) of RO5093151 from Part A or 0.005% latanoprost (topical ocular instillation) once daily for 7 days. |
| Name | Type | Description |
|---|---|---|
| Latanoprost | DRUG | Latanoprost is a ophthalmic solution, available in dose strength as 0.005%. |
| Placebo | DRUG | Matching placebo formulation will be administered in Part A. |
| RO5093151 | DRUG | RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%. |
Inclusion Criteria: * Diagnosis of ocular hypertension (OHT) or primary open angle glaucoma (POAG) in at least one eye (qualifying eye) as determined by the Investigator at screening or based on a reliable and documented assessment done within the last 6 months prior to screening provided that no p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Latanoprost is an investigational small molecule being studied for the treatment of glaucoma. It is currently in Phase 1 clinical development, meaning it has not yet been approved for any use. The drug is being evaluated in patients with primary open angle glaucoma or ocular hypertension.
Latanoprost is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this drug for the treatment of glaucoma, and it is currently in Phase 1 development.
Latanoprost is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with glaucoma.
Latanoprost has one completed clinical trial, NCT02622334, which was a Phase 1 study in patients with primary open angle glaucoma or ocular hypertension. The trial enrolled 45 participants and was conducted in the United States and Singapore. It was a randomized, double-blind, controlled study.
Yes, Latanoprost is also known as RO5093151. The clinical trial NCT02622334 investigated RO5093151, which is the same drug as Latanoprost. This alternative name may appear in scientific literature and clinical trial registries.